Avolynt is developing therapeutics for rare and metabolic disease. Avolynt's lead programs target Type 2 diabetes, NASH and Post Bariatric Hypoglycemia.
Employment range in NC
Primary site activity
All company activities
Products on market
Remogliflozin, a novel inhibitor of SGLT2, was launched in May 2019.